CDKN2A

(redirected from MTS1)
Also found in: Acronyms.

CDKN2A

A gene on chromosome 9p21 that encodes an alternate open reading frame (ARF) product, which acts as a tumour suppressor by binding to MDM2 and blocking its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits MDM2’s oncogenic activity, which would normally degrade p53, a tumour suppressor protein. CDKN2A also induces G2 arrest and apoptosis, independent of p53, by preventing the activation of cyclin B1/CDC2 complexes.

CDKN2A also binds to:
• BCL6, downregulating BCL6-induced transcriptional repression;
• E2F1 and MYC, blocking their transcriptional activator activity;
• HUWE1, repressing its ubiquitin ligase activity;
• TOP1/TOPOI, stimulating its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation.

CDKN2A interacts with:
• COMMD1 and promotes its “Lys63”-linked polyubiquitination;
• NPM1/B23, promoting its polyubiquitination and degradation and inhibiting rRNA processing;
• UBE2I/UBC9, enhacing sumoylation of some of its binding partners (e.g., MDM2 and E2F1).
References in periodicals archive ?
For inter-observer agreement with MTS, the single significant difference (MTS1 x MTS3, t(18) = 2.90, p [is less than] .01, two-tailed) is in the direction of decreasing error with increasing complexity; in the single PIR case, as expected, there is increased error with increasing complexity (PIR2 x PIR3, t(18) = 2.35, p [is less than] .05, two-tailed).
The researchers hope eventually to be able to influence this decision in tumor cells by adding back the MTS1 gene or administering a drug that mimics p16's braking activity.
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.
Female mice overexpressing calcium-binding protein S100A4/Mts1 (Mts1) were more susceptible to develop PAH and developed plexiform-like lesions [96].
Dispatch consoles to manage operations and installation of 6 new MTS1 model radio bases that can be deployed quickly to be used in tactical operations and to cover specific locations
Motorola Solutions will show future-ready technology solutions like the industry-leading WAVE Work Group Communications and MOTOTRBOTM Anywhere broadband push-to-talk that extends the reach and capability of LMR systems as well as a new software release for the Motorola MTS1 base station, enabling use as an independent base station to support requirements for in-building coverage (TMOa).
Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.